Mounjaro (Tirzepatide) injections

 

BACK TO MAIN INDEX

 

You may have seen information in the media recently about the release of NICE guidance (TA1026) Mounjaro (Tirzepatide) injections for managing Obesity and Overweight in Adults, as well as its use to treat Type 2 Diabetes.

 

Mounjaro for Obesity:

Alert

From 23rd June 2025 GPs will be able to prescribe Mounjaro on the NHS to certain cohorts of patients that meet strict eligiblity criteria.

This service has not yet been developed by NHS Devon and we are currently unable to initiate prescribing for Mounjaro to patients for Obesity until this has been agreed and developed.

Warning

NHS Devon are advising against the independent initiation of tirzepatide (Mounjaro®) prescribing for weight management until the point at which further guidance is provided.
 

Cohorts for Mounjaro prescribing in General Practice

NHS England have defined the first 3 cohorts of patients who will be able to access Mounjaro via their GP on the NHS. 

The cohorts have been decided nationally by NHS England, this is to prioritise treatment by clinical need.

The initial first 3 years will see approximately 220,000 individually nationally become eligible for treatment on the NHS. 

At a practice level, we estimate that the number of our patients eligible for Mounjaro for weight management will be less than 50. 

It is expected that after the first 3 years, the cohorts for eligibility will expand again; however this is to be confirmed. 

The interim commissioning policy from NHS England can be viewed here: Interim commissioning guidance NICE TA1026 - Mounjaro for the management of obesity

 
 

Cohort 1: 23 June 2025

PLEASE SEE ALERT ABOVE - WHILST THE NEWS HAVE ANNOUNCED THAT THIS COHORT IS NOW LIVE, THIS SERVICE HAS NOT YET BEEN DEVELOPED BY NHS DEVON AND WE ARE CURRENTLY UNABLE TO INITIATE PRESCRIBING FOR MOUNJARO TO PATIENTS FOR OBESITY UNTIL THIS HAS BEEN AGREED AND DEVELOPED. 

A BMI of 40 or higher, or 37.5 or higher if from South Asian, Chinese, other Asian, Middle Eastern, Black African or African-Caribbean ethnic backgrounds.

At least 4 of the following comorbidities:

  • Hypertension and on treatment for blood pressure
  • Dyslipidaemia (high cholesterol) or on cholesterol treatment "statins"
  • Obstructive Sleep Apnoea 
  • Cardiovascular disease 
  • Type 2 diabetes
 

Cohort 2: June 2026 (exact date to be confirmed)

A BMI of 35 or higher, or 32.5 or higher if from South Asian, Chinese, other Asian, Middle Eastern, Black African or African-Caribbean ethnic backgrounds.

At least 4 of the following comorbidities:

  • Hypertension and on treatment for blood pressure
  • Dyslipidaemia (high cholesterol) or on cholesterol treatment "statins"
  • Obstructive Sleep Apnoea 
  • Cardiovascular disease 
  • Type 2 diabetes
 

Cohort 3: April 2027 (exact date to be confirmed)

A BMI of 40 or higher, or 37.5 or higher if from South Asian, Chinese, other Asian, Middle Eastern, Black African or African-Caribbean ethnic backgrounds.

At least 3 of the following comorbidities:

  • Hypertension and on treatment for blood pressure
  • Dyslipidaemia (high cholesterol) or on cholesterol treatment "statins"
  • Obstructive Sleep Apnoea 
  • Cardiovascular disease 
  • Type 2 diabetes
 

I think I meet the criteria for Cohort 1, what do I do?

Once the service has been developed by NHS DEVON, we will contact the very small number of eligible patients. In the meantime, here are a number of local weight management services currently available for people living with obesity or overweight,  and we are happy to discuss these and support you with your weight management goals.

Here is a link to the Services available in Devon:

MyHealthDevon - Weight Management

 

Mounjaro for Type 2 Diabetes:

Alert

Mounjaro is licensed to treat some patients with type 2 diabetes under NICE TA924.

It is not suitable for everyone with Type 2 diabetes, and there are oral medications that we would prescribe first, before even considering if Mounjaro is a suitable option.

More information on the use of Mounjaro for Type 2 Diabetes can be found on the Diabetes UK site

Published: Jun 23, 2025